Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
Newly Diagnosed Amyloidosis · Amyloidosis Stage I-IIIA
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 382 (planned)
- Started
- Dec 18, 2026
- Main results expected
- Jul 25, 2035
- Fully finished
- Jul 25, 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Measured over: Up to 7 years
Severity of TEAEs
Measured over: Up to 7 years
Occurrence of Adverse Events of Special Interest (AESI)
Measured over: Up to 7 years
Severity of AESI
Measured over: Up to 7 years
Occurrence of Serious Adverse Events (SAEs)
Measured over: Up to 7 years
Severity of SAEs
Measured over: Up to 7 years
Achievement of Hematologic Complete Response (HemCR) per International Society of Amyloidosis (ISA) response criteria as determined by Blinded Independent Review Committee (BIRC)
Measured over: Up to 7 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07901725 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC